Free Trial

Eli Lilly and Company (LLY) Stock Price, News & Analysis

$909.15
+3.02 (+0.33%)
(As of 10/22/2024 ET)

About Eli Lilly and Company Stock (NYSE:LLY)

Key Stats

Today's Range
$900.20
$911.12
50-Day Range
$877.50
$960.02
52-Week Range
$547.61
$972.53
Volume
1.34 million shs
Average Volume
2.97 million shs
Market Capitalization
$864.06 billion
P/E Ratio
111.96
Dividend Yield
0.57%
Price Target
$1,002.24
Consensus Rating
Moderate Buy

Company Overview

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

Eli Lilly and Company Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
99th Percentile Overall Score

LLY MarketRank™: 

Eli Lilly and Company scored higher than 99% of companies evaluated by MarketBeat, and ranked 21st out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.84, and is based on 16 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Eli Lilly and Company has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Eli Lilly and Company's stock forecast and price target.
  • Earnings Growth

    Earnings for Eli Lilly and Company are expected to grow by 45.48% in the coming year, from $16.49 to $23.99 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eli Lilly and Company is 111.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.28.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eli Lilly and Company is 111.96, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.66.

  • Price to Earnings Growth Ratio

    Eli Lilly and Company has a PEG Ratio of 2.79. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Eli Lilly and Company has a P/B Ratio of 79.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Eli Lilly and Company's valuation and earnings.
  • Percentage of Shares Shorted

    0.68% of the float of Eli Lilly and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Eli Lilly and Company has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eli Lilly and Company has recently decreased by 12.01%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Eli Lilly and Company has a dividend yield of 0.57%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Eli Lilly and Company does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Eli Lilly and Company is 76.58%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 21.68% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.

  • Read more about Eli Lilly and Company's dividend.
  • Percentage of Shares Shorted

    0.68% of the float of Eli Lilly and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Eli Lilly and Company has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eli Lilly and Company has recently decreased by 12.01%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Eli Lilly and Company has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 44 news articles for Eli Lilly and Company this week, compared to 41 articles on an average week.
  • Search Interest

    Only 90 people have searched for LLY on MarketBeat in the last 30 days. This is a decrease of -3% compared to the previous 30 days.
  • MarketBeat Follows

    63 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Eli Lilly and Company insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.13% of the stock of Eli Lilly and Company is held by insiders.

  • Percentage Held by Institutions

    82.53% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Eli Lilly and Company's insider trading history.

LLY Stock News Headlines

Rotkreuz, Zug, Switzerland - 28th March 2021 : Roche sign in front at the Roche Diagnostics campus in Rotkreuz, Switzerland. F. Hoffmann-La Roche AG is a Swiss multinational healthcare company
Can Roche Challenge Lilly and Novo in the Weight Loss Market? (LLY)
One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.
Eli Lilly weight loss
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there.
Watch this before it gets removed
If you missed it, my emergency election broadcast is now available - but will be removed soon
Stock market trading graph in green color as economy 3D illustration background. Trading trends and economic statistics. — Photo
Top 3 Stocks with Explosive Call Option Activity: What to Watch (LLY)
Three stocks reported a surge in call option buying recently, showing investors that there could be a path to more upside potential, analysts agree
Blue injector dosing pen for subcutaneous injection of antidiabetic medication, anti-obesity medication on a blue background. Measuring tape around the injector. Drug and weight loss — Photo
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar (LLY)
Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.
Eli Lilly Earnings Preview: What to Expect
See More Headlines

LLY Stock Analysis - Frequently Asked Questions

Eli Lilly and Company's stock was trading at $582.92 on January 1st, 2024. Since then, LLY stock has increased by 56.0% and is now trading at $909.15.
View the best growth stocks for 2024 here
.

Eli Lilly and Company (NYSE:LLY) released its quarterly earnings results on Thursday, August, 8th. The company reported $3.92 EPS for the quarter, topping analysts' consensus estimates of $2.64 by $1.28. The firm earned $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a trailing twelve-month return on equity of 67.52%.

Eli Lilly and Company subsidiaries include Protomer Technologies, Prevail Therapeutics Inc., Disarm Therapeutics, Disarm Therapeutics, Dermira, Loxo Oncology, CoLucid Pharmaceuticals, and more.

Top institutional investors of Eli Lilly and Company include International Assets Investment Management LLC (1.31%), Sapient Capital LLC (0.12%), Swedbank AB (0.12%) and Handelsbanken Fonder AB (0.08%). Insiders that own company stock include Lilly Endowment Inc, Jackson P Tai, Anne E White, Patrik Jonsson, Johna Norton, Alonzo Weems, Donald A Zakrowski, Acquisition Corp Kearny, Marschall S Runge and Ilya Yuffa.
View institutional ownership trends
.

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eli Lilly and Company investors own include Broadcom (AVGO), NVIDIA (NVDA), Meta Platforms (META), BlackRock (BLK), Salesforce (CRM), Chevron (CVX) and ServiceNow (NOW).

Company Calendar

Last Earnings
8/08/2024
Ex-Dividend for 9/10 Dividend
8/15/2024
Dividend Payable
9/10/2024
Today
10/22/2024
Next Earnings (Confirmed)
10/30/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
53245710
Employees
43,000
Year Founded
1876

Price Target and Rating

Average Stock Price Target
$1,002.24
High Stock Price Target
$1,125.00
Low Stock Price Target
$723.00
Potential Upside/Downside
+10.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.84
Research Coverage
19 Analysts

Profitability

Net Income
$5.24 billion
Pretax Margin
23.09%

Debt

Sales & Book Value

Annual Sales
$38.92 billion
Cash Flow
$7.54 per share
Book Value
$11.44 per share

Miscellaneous

Free Float
949,190,000
Market Cap
$864.06 billion
Optionable
Optionable
Beta
0.42

Social Links


This page (NYSE:LLY) was last updated on 10/23/2024 by MarketBeat.com Staff
From Our Partners